anti-osteoporosis drug treatment

Overview

Anti-osteoporosis drug treatment refers to pharmacologic therapy used to prevent or reduce bone loss and lower the risk of fragility fractures in people with osteoporosis or high fracture risk. In practice, this category includes antiresorptive agents such as denosumab and Zoledronate, as well as anabolic or bone-forming therapies such as teriparatide. These treatments are selected according to fracture risk, prior fracture history, bone mineral density, comorbidities, and treatment goals.

Biologically, anti-osteoporosis drugs act by altering bone remodeling. Antiresorptive therapies suppress osteoclast-mediated bone resorption, thereby helping preserve bone mass and reduce skeletal fragility. Denosumab, for example, is an anti-RANKL antibody that inhibits osteoclast formation and activity. This mechanism is relevant not only to osteoporosis but also to the osteoimmune microenvironment and to bone-related disease contexts such as metastatic bone disease. Other agents, such as Zoledronate, are also used to reduce fracture risk, while anabolic agents like teriparatide stimulate bone formation. Recent research has also examined how these therapies may intersect with broader systemic outcomes, including immune effects and possible associations with non-skeletal diseases.

Focus of Latest Publications

Recent publications on anti-osteoporosis drug treatment have focused heavily on denosumab, examining both its therapeutic benefits and its safety profile in complex clinical settings. In a peritoneal dialysis case, denosumab was associated with increased bone mineral density over 10 months, but also with marked serum calcium fluctuations despite proactive adjustment of dialysate calcium, vitamin D therapy, and calcium supplementation. The report emphasized that early hypocalcemia can be followed by overshoot hypercalcemia when multiple corrective measures are escalated together, underscoring the need for frequent monitoring and stepwise calcium management after dosing in patients with advanced kidney disease.

Other studies have explored denosumab in special populations and broader treatment contexts. A ten-year follow-up case report described its use as an adjuvant to anterior-posterior surgery for a giant cell tumor of the cervical axis, highlighting the long-term role of denosumab in surgically challenging bone disease. In pediatric glucocorticoid-induced osteoporosis, denosumab was the subject of a feasibility assessment tied to regulatory requirements, where enrollment into a randomized controlled trial proved exceedingly low and prompted exploration of real-world epidemiologic data to better understand trial feasibility.

Several publications addressed denosumab’s potential effects beyond bone outcomes. A Mendelian randomization study investigated whether denosumab and calcitriol might influence asthma risk and lung function, while another study examined transcriptome changes in bone marrow immune cells at single-cell resolution during denosumab treatment to assess possible immunomodulatory effects and osteoimmune alterations. In addition, a study of young infertile men evaluated the impact of a single denosumab dose on glucose and lipid homeostasis, reflecting interest in possible links between anti-osteoporosis therapy and Cardiometabolic comorbidity, including glycated Hb (HbA1C).

Treatment strategy and health-system considerations were also addressed. A microsimulation analysis in Chinese postmenopausal women estimated FRAX-based thresholds for initiating osteoporosis therapy and found denosumab to be cost-effective at a 10-year major osteoporotic fracture probability of 7%, compared with higher thresholds for zoledronate and no cost-effectiveness for alendronate or teriparatide at the probabilities evaluated. Finally, mechanistic work in ER-positive breast cancer bone metastasis identified a RANKL-independent osteoclastogenesis pathway contributing to denosumab resistance and showed that pharmacologic inhibition of CARM1 could suppress osteoclastogenesis and bone metastasis in resistant models, suggesting a potential strategy to overcome treatment failure.

Key Publications

NEWJun Denosumab increased bone mineral density but caused marked serum calcium fluctuations in a patient undergoing peritoneal dialysis. (CEN case reports, 2026, PMID 42377652): "Denosumab is increasingly used to treat osteoporosis in patients with advanced kidney disease, but clinically significant disturbances in calcium homeostasis remain a major concern."
NEWJan Giant Cell Tumor of the Cervical Axis Treated With Anterior-Posterior Surgery and Denosumab: A Ten-year Follow-up Case Report. (In vivo (Athens, Greece), 2026, PMID 42379792): "Denosumab, a monoclonal antibody targeting RANKL, has emerged as an important adjuvant therapy for unresectable or surgically challenging GCTB."
NEWJun Effects of a single-dose denosumab on glucose and lipid homeostasis in young infertile men. (Endocrine, 2026, PMID 42347899): "Denosumab has been shown to lower HbA1c in older patients with impaired glucose tolerance."
NEWJun Cost-effectiveness thresholds for initiating osteoporosis treatment in postmenopausal women in China: a microsimulation analysis based on real-world data. (Archives of osteoporosis, 2026, PMID 42329508): "Denosumab became cost-effective at a 10-year major osteoporotic fracture probability of 7%, and zoledronate at 12%, whereas alendronate and teriparatide did not reach cost-effectiveness at any FRAX probability evaluated."
NEWJun Case Study on the Use of Real-World Evidence in a Feasibility Assessment of a Randomized Controlled Trial Design to Support the Fulfillment of Pediatric Requirements with the FDA and EMA. (Therapeutic innovation & regulatory science, 2026, PMID 42319705): "...for Prolia (denosumab)."
May Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis. (The Journal of clinical investigation, 2026, PMID 42138086): "Nearly 40% of patients develop progressive skeletal lesions despite denosumab therapy, highlighting an urgent need to identify resistance mechanisms and alternative therapeutic strategies."
May The impact of denosumab and calcitriol on asthma risk and lung function: a drug target mendelian randomization study. (European journal of clinical pharmacology, 2026, PMID 42104117): "we aim to investigate the causal effect of anti-osteoporosis drug treatment on chronic disease asthma through the Mendelian randomization (MR) analysis method."
Jun Deciphering transcriptome alterations in bone marrow immune cells at single-cell resolution under denosumab treatment. (International immunopharmacology, 2026, PMID 41997054): "Denosumab, an anti-RANKL antibody, effectively inhibits bone resorption, increases bone mass, and reduces fracture risk; however, its immunomodulatory effects raise concerns about possible immune imbalances during the treatment."